SCHEMBL17015695

SCHEMBL17015695

O=C(c1ccccc1)c1cccc(-n2c3ccccc3c3ccc4c(ccn4-c4ccc(-c5ccccc5)cc4)c32)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.38
SETD7 Q8WTS6 1/20 0.37
EHMT2 Q96KQ7 1/20 0.37
CNR2 P34972 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
FOLH1 Q04609 1/20 0.36
RORC P51449 3/20 0.35
ATM Q13315 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 2/20 0.35
GLA P06280 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 2/20 0.35
PKM P14618 1/20 0.35
EDNRB P24530 1/20 0.35
EDNRA P25101 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015225 0.94 CNR2 (0.40) SETD7EHMT2CNR2CA12CA1
SCHEMBL17015776 0.93 CNR2 (0.36) CYP19A1SETD7EHMT2CNR2CA12
SCHEMBL17015691 0.92 CA12 (0.38) CYP19A1CNR2CA12CA1CA2
SCHEMBL17015697 0.92 CLK1 (0.36) CYP19A1SETD7EHMT2CNR2FOLH1
SCHEMBL17016181 0.90 RORC (0.41) SETD7EHMT2CNR2CA12CA1
SCHEMBL17015222 0.89 L3MBTL1 (0.41) CNR2CA12CA1CA2CA9
SCHEMBL17016174 0.89 L3MBTL1 (0.41) CNR2CA12CA1CA2CA9
SCHEMBL17015698 0.88 MAPK1 (0.36) CYP19A1CNR2ALDH1A1GLASMN1; SMN2
SCHEMBL17015705 0.88 L3MBTL1 (0.41) ATML3MBTL1ALDH1A1KDM4EEDNRB
SCHEMBL17015771 0.87 CNR2 (0.36) CYP19A1CNR2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 CYP19A1 1414/4885SETD7 455/4885EHMT2 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.